These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Development of a Patient-Reported Outcomes Tool to Assess Pain and Discomfort in Autosomal Dominant Polycystic Kidney Disease. Oberdhan D; Cole JC; Atkinson MJ; Krasa HB; Davison SN; Perrone RD Clin J Am Soc Nephrol; 2023 Feb; 18(2):213-222. PubMed ID: 36754008 [TBL] [Abstract][Full Text] [Related]
9. Development of the Autosomal Dominant Polycystic Kidney Disease Impact Scale: A New Health-Related Quality-of-Life Instrument. Oberdhan D; Cole JC; Krasa HB; Cheng R; Czerwiec FS; Hays RD; Chapman AB; Perrone RD Am J Kidney Dis; 2018 Feb; 71(2):225-235. PubMed ID: 29150246 [TBL] [Abstract][Full Text] [Related]
10. The Association of Combined Total Kidney and Liver Volume with Pain and Gastrointestinal Symptoms in Patients with Later Stage Autosomal Dominant Polycystic Kidney Disease. D'Agnolo HMA; Casteleijn NF; Gevers TJG; de Fijter H; van Gastel MDA; Messchendorp AL; Peters DJM; Salih M; Soonawala D; Spithoven EM; Visser FW; Wetzels JFM; Zietse R; Gansevoort RT; Drenth JPH Am J Nephrol; 2017; 46(3):239-248. PubMed ID: 28881341 [TBL] [Abstract][Full Text] [Related]
11. Increased psychosocial risk, depression and reduced quality of life living with autosomal dominant polycystic kidney disease. Simms RJ; Thong KM; Dworschak GC; Ong AC Nephrol Dial Transplant; 2016 Jul; 31(7):1130-40. PubMed ID: 26268712 [TBL] [Abstract][Full Text] [Related]
12. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study. Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426 [TBL] [Abstract][Full Text] [Related]
13. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Chapman AB; Guay-Woodford LM; Grantham JJ; Torres VE; Bae KT; Baumgarten DA; Kenney PJ; King BF; Glockner JF; Wetzel LH; Brummer ME; O'Neill WC; Robbin ML; Bennett WM; Klahr S; Hirschman GH; Kimmel PL; Thompson PA; Miller JP; Kidney Int; 2003 Sep; 64(3):1035-45. PubMed ID: 12911554 [TBL] [Abstract][Full Text] [Related]
14. Core Outcome Domains for Trials in Autosomal Dominant Polycystic Kidney Disease: An International Delphi Survey. Cho Y; Rangan G; Logeman C; Ryu H; Sautenet B; Perrone RD; Nadeau-Fredette AC; Mustafa RA; Htay H; Chonchol M; Harris T; Gutman T; Craig JC; Ong ACM; Chapman A; Ahn C; Coolican H; Kao JT; Gansevoort RT; Torres V; Pei Y; Johnson DW; Viecelli AK; Teixeira-Pinto A; Howell M; Ju A; Manera KE; Tong A Am J Kidney Dis; 2020 Sep; 76(3):361-373. PubMed ID: 32359822 [TBL] [Abstract][Full Text] [Related]
15. Yinang formulation versus placebo granules as a treatment for chronic kidney disease stages III-IV in patients with autosomal dominant polycystic kidney disease: study protocol for a double-blind placebo-controlled randomized clinical trial. Gan J; Wu Y; Gong X; Ma Y; Yu S; Gao J Trials; 2019 Aug; 20(1):481. PubMed ID: 31391092 [TBL] [Abstract][Full Text] [Related]
16. The Clinical Manifestation and Management of Autosomal Dominant Polycystic Kidney Disease in China. Xue C; Zhou CC; Wu M; Mei CL Kidney Dis (Basel); 2016 Oct; 2(3):111-119. PubMed ID: 27921038 [TBL] [Abstract][Full Text] [Related]
17. RAPID-ADPKD (Retrospective epidemiological study of Asia-Pacific patients with rapId Disease progression of Autosomal Dominant Polycystic Kidney Disease): study protocol for a multinational, retrospective cohort study. Ryu H; Park HC; Oh YK; Sangadi I; Wong A; Mei C; Ecder T; Wang AY; Kao TW; Huang JW; Rangan GK; Ahn C BMJ Open; 2020 Feb; 10(2):e034103. PubMed ID: 32034027 [TBL] [Abstract][Full Text] [Related]
18. Range and Variability of Outcomes Reported in Randomized Trials Conducted in Patients With Polycystic Kidney Disease: A Systematic Review. Sautenet B; Cho Y; Gutman T; Rangan G; Ong A; Chapman AB; Ahn C; Coolican H; Tze-Wah Kao J; Fowler K; Gansevoort RT; Geneste C; Perrone RD; Harris T; Torres VE; Pei Y; Craig JC; Tong A; Am J Kidney Dis; 2020 Aug; 76(2):213-223. PubMed ID: 32171640 [TBL] [Abstract][Full Text] [Related]
19. Patient-reported outcome measures for pain in autosomal dominant polycystic kidney disease: A systematic review. Natale P; Hannan E; Sautenet B; Ju A; Perrone RD; Burnette E; Casteleijn N; Chapman A; Eastty S; Gansevoort R; Hogan M; Horie S; Knebelmann B; Lee R; Mustafa RA; Sandford R; Baumgart A; Tong A; Strippoli GFM; Craig JC; Rangan GK; Cho Y PLoS One; 2021; 16(5):e0252479. PubMed ID: 34043715 [TBL] [Abstract][Full Text] [Related]
20. Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model. Bennett H; McEwan P; Hamilton K; O'Reilly K BMC Nephrol; 2019 Apr; 20(1):136. PubMed ID: 31014270 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]